Bristol-Myers Squibb Co Stock Price, News & Analysis

Bristol Myers Squibb (NYSE:BMY) reported fourth quarter revenues of $11.4 billion, down 5% year-over-year, while full-year revenues remained stable at $46.2 billion. Fourth quarter GAAP EPS was $0.95, a decline of 11%, and non-GAAP EPS was $1.82, down 1%. Key growth drivers included in-line products, achieving revenues of $8.3 billion, up 4%, and new product portfolio revenues of $645 million, an 83% increase. Financial guidance for 2023 suggests continued revenue growth, projecting GAAP EPS between $4.03 and $4.33. Despite strong commercial performance, challenges such as generic erosion of Revlimid affected overall revenue performance.

Bristol Myers Squibb continues to lead in immuno-oncology with ongoing research into dual and triplet immunotherapy combinations, particularly focusing on the LAG-3 immune checkpoint. These combinations aim to enhance the immune response against tumors by overcoming T cell exhaustion.

The company is also exploring immunostimulatory therapies that activate the immune system directly and emphasizes a precision medicine approach to tailor treatments based on specific biomarkers. This strategic focus positions Bristol Myers Squibb at the forefront of cancer treatment advancements, addressing significant unmet clinical needs.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Reblozyl (luspatercept) for treating non-transfusion-dependent beta thalassemia in adults. This recommendation will be reviewed by the European Commission, which could lead to its third indication in the EU. The pivotal BEYOND study showed that Reblozyl significantly increased hemoglobin levels in 77% of patients, while serious adverse reactions were lower compared to placebo (11.5% vs. 25%). The EC's decision is expected within 67 days. Approval could enhance BMY's market position in Europe, where beta thalassemia prevalence is high.

Bristol Myers Squibb (NYSE: BMY) announced that the CHMP of the European Medicines Agency has recommended approval for Sotyktu (deucravacitinib) to treat adults with moderate-to-severe plaque psoriasis. This recommendation is based on positive results from Phase 3 POETYK PSO-1 and POETYK PSO-2 trials, demonstrating superior efficacy over Otezla and placebo. If approved, Sotyktu would be the first oral TYK2 inhibitor in the EU. CEO Samit Hirawat emphasized the need for effective oral therapies for patients with psoriasis. The European Commission will review the recommendation for final approval.

Bristol Myers Squibb (NYSE: BMY) announced promising topline results from the TRANSCEND CLL 004 study, a Phase 1/2 trial evaluating Breyanzi for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The study met its primary endpoint of complete response rate in patients refractory to a BTK inhibitor and treated with a BCL-2 inhibitor. No new safety signals for Breyanzi were reported. The trial represents a significant milestone as it is the first multicenter study exploring CAR T cell therapy for patients with limited treatment options.

Bristol Myers Squibb organized the 2022 C2C4C cycling event, involving over 350 employees from 23 countries who raised more than $2 million for cancer research. The journey covered nearly 7,000 miles through various global locations. Participants, including survivor Blanca Bedoya, emphasized the event's mission beyond cycling, linking personal growth with a commitment to patients. Since its inception in 2014, C2C4C has raised around $14 million for cancer initiatives worldwide. The 10th anniversary is scheduled for next year, emphasizing ongoing support for the cancer community.

Bristol Myers Squibb (NYSE: BMY) will present at J.P. Morgan’s 41^st Annual Healthcare Conference on January 9, 2023. The presentation will be led by Giovanni Caforio, M.D., the Board Chair and CEO, at 7:30 a.m. PST / 10:30 a.m. EST. A live webcast will be available at http://investor.bms.com, with additional materials accessible at the start of the event. A replay will follow. Bristol Myers Squibb is dedicated to developing innovative medicines for serious diseases.

Bristol Myers Squibb (NYSE: BMY) has finalized the sale of its manufacturing facility in Syracuse, New York to LOTTE BIOLOGICS. This divestiture aims to optimize its manufacturing network and support its product portfolio. As part of the deal, LOTTE BIOLOGICS will offer employment to all Syracuse site employees and will handle manufacturing for Bristol Myers Squibb at the same facility under a new contract manufacturing organization relationship.

Bristol Myers Squibb (NYSE:BMY) will reveal its Q4 2022 financial results on February 2, 2023, during a 9:00 a.m. ET conference call. Investors can listen via a live webcast or by dialing 888-300-3045 (U.S. toll-free) or +1 646-568-1027 (international) with conference code: 3734085. Replay options will be available post-call, accessible until February 16, 2023. For more details about the company, visit BMS.com.